Management of Steroid-Induced Hyperglycemia
For hospitalized patients with steroid-induced hyperglycemia, use either NPH-based insulin or basal-bolus insulin regimens, with NPH insulin timed to match the glucocorticoid's peak action (typically given concomitantly with morning intermediate-acting steroids like prednisone). 1, 2
Target Blood Glucose Range
Maintain blood glucose between 100-180 mg/dL (5.6-10.0 mmol/L) in hospitalized patients 1, 2. This target balances glycemic control with hypoglycemia risk and is supported by the most recent guidelines.
Insulin Regimen Selection Based on Glucocorticoid Type
For Intermediate-Acting Steroids (Prednisone, Methylprednisolone)
- NPH insulin is the preferred choice because its peak action (4-6 hours post-administration) aligns with the glucocorticoid's peak effect 2
- Administer NPH concomitantly with the morning steroid dose 2
- May add prandial insulin if needed for meal coverage 1
- Can be given in divided doses depending on timing and pharmacokinetics 1
For Long-Acting Steroids (Dexamethasone) or Multi-Dose/Continuous Use
- Long-acting basal insulin is required to manage fasting hyperglycemia 2
- Add substantial prandial and correction insulin (often 40-60% or more increases) for higher glucocorticoid doses 2
- Basal-bolus regimens provide comprehensive 24-hour coverage 1, 2
Insulin Dosing Considerations
The insulin dose matters most—body weight alone poorly predicts requirements 3. Consider these factors when calculating doses:
- Sex (affects insulin sensitivity)
- Presence of known diabetes (higher baseline requirements)
- Pre-admission glucose-lowering medications (indicates severity)
- HbA1c level (reflects baseline glycemic control)
- Glucocorticoid dose (higher doses require proportionally more insulin) 2, 3
For higher glucocorticoid doses, expect to increase insulin by 40-60% or more beyond baseline requirements 2. One study found that increasing the insulin-to-steroid ratio improved time in range, though with increased hypoglycemia risk 2.
Monitoring Strategy
Blood Glucose Monitoring
- Point-of-care testing at least every 2-4 hours while NPO 2
- Daily adjustments based on glycemia levels and anticipated changes in steroid type, dose, and duration 2
- Focus monitoring on afternoon and evening when intermediate-acting steroids cause peak hyperglycemia 2, 4
Additional Assessments
- HbA1c for baseline assessment (though less useful for short-term changes) 4
- Fructosamine better reflects short-term glycemic changes during steroid therapy 4
- Continuous glucose monitoring (CGM) can be used if available and appropriate (avoid in hypoperfusion, hypovolemia, or with interfering medications like acetaminophen >4g/day, dopamine, vitamin C, hydroxyurea) 1
Critical Management Principles
Proactive Approach
Be proactive, not reactive 5. Anticipate hyperglycemia before it becomes severe. Correction-only insulin (sliding scale alone) without basal insulin is associated with worse outcomes and higher complication rates 2.
Glucovigilance During Steroid Taper
As steroids taper, reduce insulin proportionally to prevent hypoglycemia 5. This requires daily reassessment and dose adjustments 2.
High-Risk Hypoglycemia Patients
Exercise particular caution in patients with:
- Age ≥65 years
- BMI ≤27 kg/m²
- Total daily insulin ≥0.6 units/kg
- Chronic kidney disease (eGFR <60)
- Liver failure, CVA, active malignancy
- History of hypoglycemia 1
Non-Insulin Options (Limited Role)
For stable outpatients with mild hyperglycemia only, selected non-insulin agents may be considered 4:
However, insulin remains the treatment of choice for moderate-to-severe hyperglycemia, particularly in hospitalized patients 4.
Common Pitfalls to Avoid
- Don't use correction insulin alone—always include basal insulin for hospitalized patients 2
- Don't use fixed weight-based dosing exclusively—incorporate clinical factors 3
- Don't forget to adjust insulin downward as steroids taper 5
- Don't ignore afternoon/evening hyperglycemia while focusing only on fasting glucose 2, 4
- Don't delay treatment initiation—steroid-induced hyperglycemia increases mortality, infection risk, and hospital length of stay 5, 4
Clinical Outcomes
Untreated steroid-induced hyperglycemia is associated with:
- Increased mortality and morbidity 2, 5
- Higher infection rates 5, 4
- Chemotherapy delays (in cancer patients) 4
- Prolonged hospital stays 5, 4
- Cardiovascular events 2
Effective glycemic management reduces these complications, making aggressive treatment justified despite hypoglycemia risks when properly monitored 2, 5.